Tuberculosis Drugs Market Industry Forecast till 2024
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/191
In 2015, out of 580 thousand people who were eligible for multidrug resistance tuberculosis treatment, only 125 000 (20%) were registered. Five countries, namely India, China, the Russian Federation, Indonesia, and Nigeria account for over 60% of this gap. Worldwide, the multidrug resistance tuberculosis treatment success rate was 50-52% in 2013 and in 2015, approximately 55% of reported new tuberculosis patients had a documented HIV test result. The HIV-positive tuberculosis patients on an antiretroviral therapy was around 78%. This led to the wider understanding about the ailment and government and non-governmental organizations alike are focusing on developing tuberculosis preventive treatment and increasing their access to the general populace. Thus, it would boost the tuberculosis drugs market over the forecast period.
The global tuberculosis drugs market was valued at US$ 1,333.1 million in 2015 and is expected to witness a CAGR of 23.4% during the forecast period (2016 – 2024).
With the significant increase in revenue of tuberculosis drugs market, over last decade, more than 10 chemical moiety have advanced into the clinical trial development pipeline, which include six new chemical moiety significantly and specifically developed for tuberculosis. Though there are molecules in clinical development phase, the global drug pipeline for tuberculosis is still not sufficient to address the unmet needs of treatment. Many pharmaceutical companies have produced molecules that are under clinical trials and the key challenges by any company to develop new product to treat tuberculosis and effects the tuberculosis drugs market are the needs for drugs in combination therapy, new trial strategies, studies on pediatric TB drugs, population and increased clinical trial capacity and clear regulatory guidelines.
High funding for research and development and clinical trials drugs to boost the tuberculosis drugs market
There was around US$ 6.6 billion revenue accessible for tuberculosis care and prevention in many of the low and middle-income countries in 2016, out of which 84% was from domestic sources. However, national tuberculosis program (NTPs) in low income countries linger to depend on international donors or foreign healthcare agencies to fund them approximately 90%. Investments in low income countries and middle income countries declined by US$ 2 billion to US$ 8.3 billion, which was needed in 2016. There were many enhancements needed in overall healthcare financing to curb new tuberculosis cases proportionally boosting tuberculosis drugs market. Government expenditures on healthcare in specific to tuberculosis in 2014 were less than the World Health Organization set a benchmark of at least 6% of gross domestic product in around 150 countries.
Ask for customization @ https://www.coherentmarketinsights.com/insight/request-customization/191
Private expenditures surpassed 45% of total healthcare expenditures in tuberculosis in 46 countries, which also includes 11 of the 30 high tuberculosis burden countries. Presently, there are around 13 vaccine candidates in clinical development, which include trial drugs for prevention of tuberculosis infection and trial drugs for prevention of tuberculosis disease in people with Latent Tuberculosis Disease. According to WHO, at least US$ 2 billion investment is needed every year for tuberculosis research and development. In stark contrast, capital investment during 2005–2014 was reported to be US$ 0.7 billion annually. Infusion of investments in research and development would significantly improve the tuberculosis drugs market outlook.
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tuberculosis Drugs Market Industry Forecast till 2024 here
News-ID: 1209815 • Views: 142
More Releases from Coherent Market Insights
Neuroscience Market - The Boon for Neurology Sector | Siemens Healthineers, Scie …
Global Neuroscience Market Report that covers exclusive and analytical data through the span of seven years between 2020-2026. This report is exclusive and encompasses in-depth analysis and industry insights on Global Neuroscience Market. What you will get by reading the report is not just charts, bars, analytical data but also a better understanding of the market which will in turn help you make decisions in the better interest of your
Plant-based Biologics Market - expected to be the next major commercial developm …
Global Plant-based Biologics Market Report that covers exclusive and analytical data through the span of seven years between 2020-2026. This report is exclusive and encompasses in-depth analysis and industry insights on Global Plant-based Biologics Market. What you will get by reading the report is not just charts, bars, analytical data but also a better understanding of the market which will in turn help you make decisions in the better interest
Ramosetron Hydrochloride Market by Indication and Application With Major Players …
Global Ramosetron Hydrochloride Market Report that covers exclusive and analytical data through the span of seven years between 2020-2026. This report is exclusive and encompasses in-depth analysis and industry insights on Global Ramosetron Hydrochloride Market. What you will get by reading the report is not just charts, bars, analytical data but also a better understanding of the market which will in turn help you make decisions in the better interest
U.S. Vaccine Market Report 2020 | Sanofi Pasteur, GlaxoSmithKline Plc, Merck & C …
Coherent Market Insights announced that it’s published an exclusive report namely Global U.S. Vaccine Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide U.S. Vaccine Market. This is an informative study covering
More Releases for Tuberculosis
Tuberculosis Vaccine Market Opportunity Analysis, 2018-2026
Tuberculosis (TB) is a highly contagious disease caused by the bacterium known as Mycobacterium tuberculosis and is mostly spread through person to person contact. It causes multisystem infection and eventually might lead to death of the infected person. Two types of TB that are commonly observed include latent TB in which the infected person do not show symptoms and active TB in which the infected person shows clinical symptoms of
Tuberculosis Diagnosis and Treatment Market
The Global Tuberculosis diagnosis and treatment market is relied upon to develop at a CAGR of 2.3 % amid 2017-2022. An irresistible illness caused by the bacterium Mycobacterium tuberculosis (MTB) is known as Tuberculosis (TB). Tuberculosis by and large influences the lungs yet can likewise influence different parts of the body. Inert tuberculosis is the sort of TB which don't have indications. Around 10% of inert contaminations advance to dynamic
Global Tuberculosis Diagnostics Sales Market Report 2018
The Global Tuberculosis Diagnostics Sales Market Report 2018 is a professional and in-depth study on the current state of the Tuberculosis Diagnostics industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Tuberculosis Diagnostics Industry analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This
Tuberculosis Testing Market | Analysis & Trends 2020
Key players in the Global Tuberculosis (TB) Testing Market, according to a report by Transparency Market Research, are Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Hain Lifescience GmbH, Hologic Inc. QIAGEN, Abbott Laboratories, Alere Inc., Epistem plc, Cepheid, bioMérieux SA, Akonni Biosystems Inc., and Sanofi. Among them, the top players namely, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, and Hain Lifescience GmbH
Tuberculosis Testing Market to Increasing Tuberculosis Awareness and Control Pro …
A new Transparency Market Research report states that the global tuberculosis testing market stood at US$1.9 bn in 2013 and is predicted to reach US$2.6 bn by 2020. It is predicted to expand at a CAGR of 4.30% from 2014 to 2020. The title of the report is “Tuberculosis Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020.” As per the report, the rising acceptance
Tuberculosis: A Neglected Pandemic
The German Center for Research and Innovation (GCRI), in cooperation with the Max Planck Florida Institute, will host a discussion on the treatments and challenges of tuberculosis on Thursday, March 31, from 7:00 to 9:00 p.m. The event will take place at the German House New York (871 United Nations Plaza, First Avenue, btw. 48th & 49th Streets). Tuberculosis, along with HIV/AIDS, is one of today’s deadliest threats. Killing one